Markman M - Search Results

1

Progress in the management of gynecologic cancer: consensus summary statement.

Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP 3rd, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. Cannistra SA, et al. Among authors: markman m. J Clin Oncol. 2003 May 15;21(10 Suppl):129s-132s. doi: 10.1200/JCO.2003.04.003. J Clin Oncol. 2003. PMID: 12743127 No abstract available.

2

Liposomal anthracycline treatment for ovarian cancer.

Markman M, Gordon AN, McGuire WP, Muggia FM. Markman M, et al. Semin Oncol. 2004 Dec;31(6 Suppl 13):91-105. doi: 10.1053/j.seminoncol.2004.08.004. Semin Oncol. 2004. PMID: 15717739 Review.

3

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP; Gynecologic Oncology Group Study. Winter WE 3rd, et al. Among authors: markman m. J Clin Oncol. 2007 Aug 20;25(24):3621-7. doi: 10.1200/JCO.2006.10.2517. J Clin Oncol. 2007. PMID: 17704411

4

Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.

Rose PG, Markman M, Bell JG, Fusco NL. Rose PG, et al. Among authors: markman m. Gynecol Oncol. 2006 Aug;102(2):236-9. doi: 10.1016/j.ygyno.2005.12.003. Epub 2006 Jan 18. Gynecol Oncol. 2006. PMID: 16412499 Clinical Trial.

5

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.

Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK. Tian C, et al. Among authors: markman m. Cancer. 2009 Apr 1;115(7):1395-403. doi: 10.1002/cncr.24152. Cancer. 2009. PMID: 19195045 Free PMC article. Review.

6

Chemotherapy: A new standard combination for recurrent ovarian cancer?

Bast RC Jr, Markman M. Bast RC Jr, et al. Among authors: markman m. Nat Rev Clin Oncol. 2010 Oct;7(10):559-60. doi: 10.1038/nrclinonc.2010.152. Nat Rev Clin Oncol. 2010. PMID: 20877420 Free PMC article.

7

Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.

Rose PG, Greer BE, Horowitz IR, Markman M, Fusco N. Rose PG, et al. Among authors: markman m. Gynecol Oncol. 2007 Jan;104(1):114-9. doi: 10.1016/j.ygyno.2006.07.036. Epub 2006 Sep 7. Gynecol Oncol. 2007. PMID: 16959305 Clinical Trial.

8

Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.

Markman M, Brady M, Hutson A, Berek JS. Markman M, et al. Int J Gynecol Cancer. 2009 Feb;19(2):223-9. doi: 10.1111/IGC.0b013e31819bdc7e. Int J Gynecol Cancer. 2009. PMID: 19395997 Free PMC article.

9

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.

Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. Zorn KK, et al. Among authors: markman m. Cancer. 2009 Mar 1;115(5):1028-35. doi: 10.1002/cncr.24084. Cancer. 2009. PMID: 19156927 Free PMC article.

10

Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.

Markman M, Zanotti K, Webster K, Belinson J, Rose P. Markman M, et al. Oncology (Williston Park). 2003 May;17(5 Suppl 5):34-5. Oncology (Williston Park). 2003. PMID: 12800604 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

814 results

Search Page